The UK National Institute for Health and Care Excellence (NICE) has recommended Andembry (garadacimab) for the prevention of hereditary angioedema (HAE) attacks, biopharmaceutical company CSL Behring has announced. The recommendation follows results from the Phase III VANGUARD trial, which found garadacimab significantly reduced the mean number of… Read More
CSL Behring Germany has announced that the first haemophilia B patient in Germany was treated with the gene therapy Hemgenix (etranacogene dezaparvovec) at the Hemophilia Treatment Center at Hannover Medical School. Hemgenix is the first one-time gene therapy approved in Europe for the treatment of adults with severe… Read More
Following the news that the first patients in Denmark with haemophilia B had been treated with Hemgenix (etranacogene dezaparvovec) gene therapy since European Commission approval, DDW’s Megan Thomas spoke with Dr Fredrik Sjöö, Head of Medical Affairs in the Nordic Region at CSL Behring, as well as Radovan Tomic, Global Market Access Director… Read More
